Amicus Therapeutics (NASDAQ:FOLD) Announces Quarterly Earnings Results
Amicus Therapeutics (NASDAQ:FOLD) reported its quarterly earnings, with an EPS of $0.10, missing the consensus estimate of $0.13. The company's revenue of $185.21 million was largely in line with expectations. Despite a negative net margin of 2.35%, Amicus Therapeutics showed a positive return on equity of 6.95%, and its stock traded near its 12-month high.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics reported strong full-year 2025 financial results, with total revenue reaching $634.2 million, an increase of 17% year-over-year at constant exchange rates. The company also announced a cash position of $293.5 million, a $44 million increase from the previous year. Amicus's proposed acquisition by BioMarin for $4.8 billion is expected to close in Q2 2026, with regulatory clearances already underway.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics has announced its full-year 2025 financial results, reporting significant revenue growth and improved financial performance. The company's total revenues reached $634.2 million, a 17% increase year-over-year, driven by strong sales of Galafold and Pombiliti + Opfolda. Amicus also revealed its definitive agreement to be acquired by BioMarin Therapeutics for approximately $4.8 billion, a transaction expected to close in Q2 2026.
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
Amicus Therapeutics reported strong full-year 2025 financial results, with total revenues reaching $634.2 million, a 17% increase year-over-year at constant exchange rates. The company also announced a cash position of $293.5 million, up $44 million from 2024. These results come as Amicus anticipates its acquisition by BioMarin Therapeutics, expected to close in Q2 2026.
AMICUS THERAPEUTICS, INC. SEC 10-K Report
Amicus Therapeutics, Inc. has released its annual Form 10-K report, detailing significant financial growth with net product sales of $634.2 million and a reduced net loss, driven by the strong performance of Galafold® and Pombiliti® + Opfolda®. The report highlights strategic initiatives including new product launches, pipeline expansion through licensing DMX-200, and a pending merger with BioMarin Pharmaceutical Inc. The company also addresses key challenges and risks, such as the BioMarin transaction, reliance on key products, and regulatory and market risks.
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
TD Cowen has maintained a Hold rating on Amicus Therapeutics (FOLD) with a $14.50 price target, despite the company's strong fourth-quarter and full-year 2025 revenue performance, particularly from its Fabry disease medication, Galafold. The cautious stance is primarily due to BioMarin's agreement to acquire Amicus for $14.50 per share, which limits the potential for significant share price appreciation beyond deal-spread dynamics as the acquisition is expected to close by Q2 2026. Amicus Therapeutics specializes in developing medicines for metabolic diseases.
TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections
TD Cowen has maintained a Hold rating and a $14.50 price target on Amicus Therapeutics (FOLD), despite the company's Q4 and full-year 2025 revenue exceeding expectations, primarily due to strong performance from its Fabry disease medication, Galafold. The caution stems from BioMarin's agreement to acquire Amicus for $14.50 per share, which limits the potential for further stock appreciation beyond deal-spread dynamics and low-probability transaction risks. The acquisition is expected to close by Q2 2026, subject to regulatory and shareholder approvals.
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC
MLex reported that BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of Amicus Therapeutics received early termination approval from the US Federal Trade Commission. This decision came on February 11, ahead of the Hart-Scott-Rodino Act waiting period's original expiration date of February 20. The transaction is anticipated to conclude in the second quarter of 2026.
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
Amicus Therapeutics (FOLD) is expected to report Q4 and full-year 2025 results, with investor focus on sales of its marketed products, Galafold and Pombiliti + Opfolda. The company has a history of earnings misses but its stock has significantly outperformed the industry. A key development is its pending acquisition by BioMarin Pharmaceutical (BMRN) for $4.8 billion, which is expected to close in Q2 2026.
Amicus Therapeutics (FOLD) to Release Earnings on Wednesday
Amicus Therapeutics (FOLD) is set to release its Q4 2025 earnings before market open on Wednesday, February 18, 2026, with analysts anticipating $0.13 EPS. Over the last quarter, insiders sold a significant number of shares, and institutional investors have adjusted their holdings. Wall Street maintains a consensus "Hold" rating for FOLD, with an average price target of $15.55.
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?
Amicus Therapeutics (NASDAQ:FOLD) shares recently traded above their 200-day moving average, reaching $14.29 before closing at $14.28. While the company beat Q3 earnings expectations with a 19.5% revenue increase, investor sentiment is mixed, with a consensus "Hold" rating amid recent downgrades and significant insider selling totaling approximately $4.49 million in the last 90 days.
Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential
Amicus Therapeutics (NASDAQ: FOLD) is a biotechnology company focused on rare disease treatments like Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, boasting a $4.48 billion market cap and 19.50% revenue growth despite being unprofitable. The company exhibits a bullish stock trend, trading above its 50-day and 200-day moving averages, and maintains positive free cash flow. Analysts have a "hold" consensus with a $14.50 target price, reflecting cautious optimism about its future growth and ability to commercialize pipeline candidates.
Amicus Therapeutics Presents New Long-term Data for both
Amicus Therapeutics announced the presentation of new long-term data for Galafold® (migalastat) for Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) for late-onset Pompe disease at the 22nd Annual WORLDSymposium™ 2026. The data, derived from clinical and real-world studies, reinforce the effectiveness of these treatments. The company highlighted several oral and poster presentations covering various aspects like real-world effectiveness, long-term outcomes, and patient-reported experiences for both diseases.
Amicus to present new data on rare disease treatments at symposium
Amicus Therapeutics (NASDAQ:FOLD) will present new data from clinical and real-world studies of its treatments for Fabry disease and late-onset Pompe disease at the 22nd Annual WORLDSymposium 2026. The biopharmaceutical company, valued at $4.49 billion with 21.28% revenue growth, will highlight findings on Galafold and Pombiliti + Opfolda. This news follows strong Q3 2025 earnings and an announced $4.8 billion acquisition by BioMarin Pharmaceutical, which has led to analyst downgrades.
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Amicus Therapeutics announced the presentation of new long-term data for Galafold (migalastat) for Fabry disease and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat) for late-onset Pompe disease at the 22nd Annual WORLDSymposium™ 2026. The presentations include results from clinical and real-world studies, highlighting the effectiveness and safety of these treatments. The data emphasizes the ongoing commitment of Amicus Therapeutics to advancing the understanding and treatment of both Fabry and Pompe diseases.
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Amicus Therapeutics presented new long-term data for its Fabry disease treatment, Galafold (migalastat), and its Pompe disease treatment, POMBILITI + OPFOLDA, at the 22nd Annual WORLDSymposium™ 2026. The data comes from both clinical and real-world studies, further supporting the efficacy and safety of these medicines. The symposium will feature several oral and poster presentations detailing outcomes related to muscle function, biomarkers, cardiac and renal effectiveness, and patient-reported outcomes.
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Amicus Therapeutics announced new long-term data for its treatments Galafold for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease. These findings are being presented at the 22nd Annual WORLDSymposium™ 2026 and stem from both clinical and real-world studies, reinforcing the therapeutic benefits of these medicines. The company expressed gratitude to patients, families, and investigators for their contributions to these scientific advancements.
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
Jefferies downgraded Amicus Therapeutics, Inc. (FOLD) to Buy from Hold and lowered its price target to $14.50 from $16.00, following reports of takeover interest beyond BioMarin. This adjustment comes after BioMarin officially announced its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction at $14.50 per share, significantly valuing the company's therapies for Fabry and Pompe diseases. Amicus Therapeutics specializes in developing treatments for rare and orphan genetic disorders.
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments
Jefferies has downgraded Amicus Therapeutics, Inc. (FOLD) to Buy from Hold and lowered its price target to $14.50 from $16.00, despite significant takeover interest in the company. This downgrade follows BioMarin's announcement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction, valuing the company at approximately $4.8 billion. The acquisition will add key therapies for Fabry and Pompe diseases to BioMarin's portfolio.
Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain?
Amicus Therapeutics (FOLD) saw a 48.9% gain last year, raising questions about its current valuation. Simply Wall St assigns it an "undervalued" score, with a Discounted Cash Flow (DCF) analysis suggesting a 76.3% discount to its intrinsic value and its Price/Sales ratio also indicating it's inexpensive compared to industry averages and its proprietary Fair Ratio. The article encourages investors to use "Narratives" for personalized valuation analysis.
Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain?
Amicus Therapeutics (FOLD) saw a 48.9% gain last year, and a recent valuation by Simply Wall St suggests it is currently undervalued. The analysis, using Discounted Cash Flow (DCF) and Price-to-Sales (P/S) ratios, indicates a significant discount to its estimated intrinsic value and trades below its fair P/S ratio. Investors are encouraged to explore different valuation narratives to align with their own expectations.
Y Intercept Hong Kong Ltd Sells 723,540 Shares of Amicus Therapeutics, Inc. $FOLD
Y Intercept Hong Kong Ltd significantly reduced its stake in Amicus Therapeutics by selling 723,540 shares, bringing its holdings down to 0.09% of the company. This comes as company insiders also sold a substantial number of shares, totaling $4.73 million in the last quarter, though insiders still retain about 2.20% ownership. Despite beating quarterly EPS and revenue estimates, analysts maintain a "Hold" rating for Amicus Therapeutics, with the stock trading near its 1-year high.
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by Zacks Research
Zacks Research has downgraded Amicus Therapeutics (NASDAQ:FOLD) from a "strong-buy" to a "hold" rating, citing recent analyst adjustments. This follows several other firms, including Leerink Partners and TD Cowen, also lowering their ratings and price targets on the biopharmaceutical company. Despite the downgrades, Amicus Therapeutics reported stronger-than-expected quarterly earnings and revenue.
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Upside with Strategic Growth in Rare Disease Therapeutics
Amicus Therapeutics (FOLD) is a biotechnology company focused on rare diseases, currently trading at $14.29 with a market cap of $4.48 billion. While not yet profitable (negative EPS and ROE), analysts are cautiously optimistic due to robust revenue growth (19.50%) and positive future earnings outlook, reflected in a forward P/E of 22.07. The company's strategic position in niche markets, particularly with products like Galafold and Pombiliti + Opfolda, and collaborations like with GSK, signal significant growth potential despite the inherent risks in biotech.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages
Amicus Therapeutics (NASDAQ:FOLD) has been assigned a consensus "Hold" rating by fourteen brokerages, with an average one-year target price of $15.55. Despite beating Q3 earnings and revenue estimates, the company reported a negative net margin and PE ratio. Recent insider selling activity totaling $4.73 million has also been noted.
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the fairness of the proposed sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share. The firm is examining whether Amicus and its board breached their fiduciary duties by not securing the best possible consideration for shareholders, ensuring the offer is adequate, or disclosing all material information. Amicus shareholders are encouraged to contact the law firm to learn about their legal options.
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics CEO Bradley Campbell sold 75,000 shares of FOLD stock for $1.07 million on January 20th, reducing his ownership by 6.84%. The stock traded near its 1-year high, reflecting recent strength, despite several analysts downgrading it to "Hold" with a consensus price target of $15.55. The company recently beat EPS and revenue estimates, though it maintains a negative net margin.
Amicus Therapeutics CEO Campbell sells $1.07 million in shares
Amicus Therapeutics (NASDAQ:FOLD) CEO Campbell Bradley L sold 75,000 shares of common stock for $1.07 million, following the exercise of options for an equal number of shares. This transaction occurred as the company's shares traded near their 52-week high, and comes amidst news of Amicus Therapeutics exceeding third-quarter earnings expectations and an announced acquisition by BioMarin Pharmaceutical for $4.8 billion. Analysts have adjusted their ratings post-acquisition announcement.
Amicus Therapeutics CEO Sells 75,000 Shares
Bradley L. Campbell, President and CEO of Amicus Therapeutics, sold 75,000 shares of the company's common stock for over $1 million on January 20, 2026. The transaction was executed under a Rule 10b5-1 trading plan established in September 2025. Following the sale, Campbell directly owns 1,021,180 shares of Amicus Therapeutics.
A Look At Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum
Amicus Therapeutics (FOLD) has seen significant share price momentum, returning 69% in the last 3 months, though long-term holders have faced declines. The company trades at a Price-to-Sales (P/S) ratio of 7.4x, which is below both its peers and the wider US Biotech industry, suggesting undervaluation. Additionally, a Discounted Cash Flow (DCF) model indicates a fair value of US$59.94 per share, significantly higher than its current US$14.35 price, reinforcing the idea of potential undervaluation despite ongoing net losses.
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook
Jefferies downgraded Amicus Therapeutics (NASDAQ:FOLD) from Buy to Hold, lowering its price target to $14.50, aligning with the stock's current trading price following the impending acquisition by BioMarin Pharmaceutical. The downgrade was prompted by proxy documents indicating limited alternative bids and BioMarin's prior interest being contingent on resolved litigation. Despite Amicus's strong financial performance, Jefferies expects the $4.8 billion acquisition to proceed as planned.
Is It Time To Reconsider Amicus Therapeutics (FOLD) After 52% One Year Share Price Gain?
Amicus Therapeutics (FOLD) has seen a 52% share price gain over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 76.1% at its current price of US$14.33, with an estimated intrinsic value of $59.96 per share. The company's Price-to-Sales (P/S) ratio of 7.40x is also below the industry average and Simply Wall St's proprietary "Fair Ratio," indicating potential undervaluation based on that metric as well.
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD
Nordea Investment Management AB has acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD), purchasing 997,780 shares valued at approximately $7.84 million. This investment makes Nordea Investment Management AB the owner of about 0.32% of Amicus Therapeutics. Other institutional investors have also adjusted their positions in the biopharmaceutical company, which recently reported strong quarterly earnings and is the subject of varied analyst ratings.
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?
Amicus Therapeutics (FOLD) shares have surged 136% in the past six months, driven by strong product performance and an impending acquisition by BioMarin Pharmaceutical (BMRN) for $4.8 billion. While Amicus's Galafold and Pombiliti + Opfolda drugs show strong demand, the company faces competition from larger pharmaceutical companies like Sanofi (SNY). Investors are advised to view FOLD as an event-driven trade due to the acquisition, with a Zacks Rank #1 (Strong Buy) recommendation for short-term gains.
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com
Amicus Therapeutics (FOLD) shares reached a new 52-week high of $14.36, reflecting a 54.85% increase over the past year and strong investor confidence. This follows a robust Q3 2025 earnings report that surpassed analyst expectations and an announcement of BioMarin Pharmaceutical's $4.8 billion acquisition of Amicus, which subsequently led to analyst downgrades from Leerink Partners and TD Cowen.
Amicus Therapeutics stock hits 52-week high at 14.36 USD By Investing.com
Amicus Therapeutics (FOLD) recently hit a 52-week high of $14.36, representing a 54.85% stock value increase over the past year due to strong investor confidence and positive market sentiment. The company also surpassed Q3 2025 earnings and revenue expectations, driven by strong product sales. BioMarin Pharmaceutical announced an all-cash acquisition of Amicus Therapeutics for $4.8 billion ($14.50 per share), which led to a downgrade from several analysts.
Amicus Therapeutics stock hits 52-week high at 14.36 USD
Amicus Therapeutics (FOLD) stock reached a 52-week high of $14.36, representing a 54.85% increase over the past year, reflecting strong investor confidence. This surge follows a strong Q3 2025 earnings report which surpassed analyst expectations, and a $4.8 billion all-cash acquisition offer from BioMarin Pharmaceutical. However, analyst ratings were subsequently downgraded to Market Perform/Hold due to the acquisition.
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum
Amicus Therapeutics (FOLD) has garnered investor attention, with its shares trading around $14.32 and exhibiting strong recent momentum. While the company is deemed slightly undervalued with a fair value of $14.80, this valuation relies on ambitious growth and the successful progression of its narrow product pipeline, presenting both opportunities and risks for investors.
Amicus Therapeutics stock hits 52-week high at 14.36 USD
Amicus Therapeutics Inc. (FOLD) stock reached a new 52-week high of $14.36, reflecting investor confidence and a 54.85% increase over the past year. This surge follows strong third-quarter 2025 earnings which surpassed analyst expectations, and a recent acquisition announcement by BioMarin Pharmaceutical for $4.8 billion, valuing Amicus at $14.50 per share. Analysts have since downgraded Amicus Therapeutics to Market Perform or Hold, with price targets adjusted to the acquisition price.
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: 19.5% Revenue Growth and Potential Upside Attract Investors
Amicus Therapeutics, Inc. (FOLD), a biotechnology company focused on rare diseases, is drawing investor and analyst attention due to its 19.5% revenue growth and strategic advancements, despite flat recent stock performance. The company's $4.42 billion market cap and innovative products like Galafold and Pombiliti + Opfolda contribute to a positive outlook with an average target price of $14.80, suggesting a potential upside of 3.64%. While challenges like a negative EPS and overbought technical indicators exist, Amicus's robust pipeline and focus on growth offer long-term potential in the healthcare market.
BioMarin Expands Rare Disease Portfolio With $4.8 Billion Amicus Acquisition
BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, expected to close in Q2 2026. This acquisition will expand BioMarin's rare disease portfolio with two marketed therapies for lysosomal storage disorders and DMX-200, a Phase 3 kidney disease candidate. The deal is anticipated to accelerate BioMarin's revenue growth and be accretive to non-GAAP diluted earnings per share within 12 months.
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum
Amicus Therapeutics (FOLD) has seen significant share price momentum, rising 46% in the past month and 72% in three months. Despite this, a popular narrative suggests the stock is still 3.5% undervalued, with a fair value of US$14.80 compared to its last close of US$14.28. This potential undervaluation is attributed to progress in its late-stage pipeline, FDA regulatory alignment, and a clear path to near-term GAAP profitability, though risks like product underperformance or pricing pressures could change this outlook.
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver
This article analyzes BioMarin Pharmaceutical Inc.'s (BMRN) acquisition of Amicus Therapeutics, highlighting its role in stabilizing cash flow through Galafold while Voxzogo continues to be a key growth driver. The report from HC Wainwright suggests that this strategic move positions BioMarin for continued growth and financial stability.
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at Guggenheim
Guggenheim has downgraded Amicus Therapeutics (NASDAQ:FOLD) from "strong-buy" to "hold," with the stock now holding an average "Hold" rating and a price target of $15.67. Despite beating earnings expectations and achieving 19.5% revenue growth, the company maintains a negative net margin and P/E ratio, while insiders have recently been net sellers. Other analysts have also adjusted their ratings and price targets for FOLD.
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume Increase - Still a Buy?
Amicus Therapeutics (NASDAQ:FOLD) experienced a significant 96% increase in trading volume on Monday, with 15,846,485 shares traded, while its stock price remained around $14.24. Despite beating recent earnings estimates, the company remains unprofitable with a negative P/E ratio, and analysts are mixed, with an average "Hold" rating and recent insider selling. The volume surge prompts a re-evaluation of whether the stock is still a compelling buy.
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver
This article from HC Wainwright discusses how BioMarin's acquisition of Amicus is expected to stabilize its cash flow. It also highlights that Voxzogo will continue to be a key growth driver for the company in the near term.
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics
BioMarin Pharmaceuticals has entered a definitive $4.8 billion all-cash agreement to acquire Amicus Therapeutics. This acquisition is set to significantly expand BioMarin's rare disease portfolio with established Fabry and Pompe franchises, adding late-stage pipeline assets and accelerating revenue growth. The deal, unanimously approved by both boards, is expected to be immediately accretive to BioMarin's non-GAAP diluted EPS in the initial 12 months post-close and strengthen its long-term financial performance.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has received a consensus "Hold" rating from analysts, with an average 1-year price target of $15.67, though some recent cuts put targets closer to $14.50. The company recently reported strong earnings, beating estimates with $0.17 EPS and demonstrating 19.5% year-over-year revenue growth. However, insider selling and a high valuation, with shares trading near their 52-week high and a negative P/E, raise some concerns.
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN)
BioMarin Pharmaceutical Inc. (BMRN) is acquiring Amicus Therapeutics, Inc. (FOLD) for $14.50 per share, a move expected to be beneficial and accretive for both companies, potentially doubling Amicus's market reach. While BMRN's Voxzogo growth is decelerating and Roctavian is slated for divestment, the acquisition is revenue-accretive, with a 27% upside and a compelling call option in DMX-200. Conversely, FOLD is rated a Hold due to its current valuation and the anchoring effect of BioMarin's offer.
Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC significantly increased its stake in Amicus Therapeutics (NASDAQ:FOLD) by 24.4% in the third quarter, now owning over 3.4 million shares worth $27.07 million. Despite recent insider selling by the CEO and other insiders, Amicus Therapeutics exceeded Q3 expectations with an EPS of $0.17 and revenue of $169.06 million, a 19.5% year-over-year increase. Analysts, however, remain mixed on the stock, holding a consensus "Hold" rating with an average target price of $15.81.
